Printer-friendly version
The dermaPACE® System utilizes extracorporeal shock wave technology for the treatment of diabetic foot ulcers, eliciting a cellular response in the wound. CPT® codes: 0512T, 0513T.
• Utilizes high-energy, focused shock waves for wound care
• Non-invasive, short treatment period
• Triggers cellular response for growth factor up-regulation, inflammatory modulation, and angiogenesis/micro-vascularization
• Improves micro-circulation
The dermaPACE® System is US FDA cleared for the treatment of diabetic foot ulcers.
Outside US: acute and chronic conditions of the skin.
Do not treat malignancies, lung and head area, coagulation disorders, children, pregnant patients, wounds greater than 16sq cm, BMI greater than or equal to 40 or patients on dialysis.
Reddening, bruising, tingling, numbness, brief increase of pain is possible, infection (wound), infection beyond the wound.
Store at room temperature.
| Contact manufacturer for more details | ● |
| Educational Material Available | ● |
| Free Samples/Trials Available | ● |
| Published Clinical Article Available | ● |
Diabetic Foot
The dermaPACE® System transfers non-invasive shock wave pulses using therapy applicator into patient using gel as a transmission medium.
As determined by treating clinician.
As determined by treating clinician.
High voltage generator/switch console, high voltage cable, therapy applicator.
One year
Requires 120V AC source
SANUWAVE, Inc. is a leader in the development and commercialization of high-energy, focused shock wave technology for the repair and regeneration of conditions of the skin.